Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Primary myxofibrosarcoma of the parotid: case report

  • Xu Li1,
  • Xin Chen1,
  • Zhao-Hui Shi1,
  • Yang Chen1Email author,
  • Jing Ye2,
  • Li Qiao1 and
  • Jian-Hua Qiu1
BMC Cancer201010:246

https://doi.org/10.1186/1471-2407-10-246

Received: 30 December 2009

Accepted: 1 June 2010

Published: 1 June 2010

Abstract

Background

Myxofibrosarcoma is common in the extremities of elderly people and is characterized by a high frequency of local recurrence.

Case presentation

We report a 37 year old female who presented with a 4-month history of facial pain and a 3-month history of painful progressive swelling in the preauricular area. She underwent a total parotidectomy. The tumor was histopathologically and immunohistochemically diagnosed as a low-grade myxofibrosarcoma. The patient was free of disease 9 months after surgery with uneventful post-operative clinical course.

Conclusions

Parotid area swelling should always alert doctors. To our knowledge, this is the first case of parotid myxofibrosarcoma. It should be added to the differential diagnosis of diseases of the parotid. We have to recognize this disease and seek adequate treatment for it.

Background

Myxofibrosarcoma is a fibroblast-derived sarcoma with character of myxoid areas in association with varying proportions of cellular areas showing a pleomorphic storiform pattern. It grows commonly in the subcutaneous of the extremities of elderly people, with rare occurrences in the head and neck (2.7%) [1].

Here we report a case of low-grade myxofibrosarcoma, arising in the parotid, and review the clinical, radiological and histopathological characteristics of this neoplasm. To our knowledge, such a presentation of parotid myxofibrosarcoma has not been reported before.

Case presentation

A 37-year-old woman presented with a 4-month history of right facial pain and a 3-month history of progressive painful swelling beneath the right ear lobe. Examination revealed a soft swelling in the anteroinferior auricular area. The mass was smooth, elastic, mobile and painful on pressure, not fluctuant. The facial nerve function was normal. The cervical lymph node was not palpable. There were no systemic symptoms. The patient was screened for metastases, and no lung or abdomen lesion was detected. Sonography revealed solid echo in right parotid gland and cervical lymph node swelling. A contrast enhanced CT scan revealed a well defined soft tissue mass in right deep parotid lobe (Figure 1).
Figure 1

CT scan of the patient. A contrast enhanced Computed tomography (CT) scan revealed a well defined soft tissue mass (40 mm × 25 mm, arrow) in the right deep parotid lobe.

The standard parotidectomy was performed. A 10 mm × 10 mm superior deep lateral cervical lymph node was resected simultaneously. The rapid intraoperative pathological diagnosis showed the samples from the mass low-grade malignancy and no metastases in the lymph node. Therefore the mass was removed with surgical margin of 1 cm radius around it and preservation of the facial nerve. The surgical margin was microscopically free of tumor. A closed vacuum drainage system was used.

Macroscopically, the tumor was a grayish-red collagenous mass intermingled with myxoid. Main stem of the facial nerve and the sternocleidomastoid muscle were involved (Figure 2). The excised specimen measured 60 mm × 25 mm × 30 mm.
Figure 2

Relationship between tumor and facial nerve represented during surgery. The tumor was a grayish-red collagenous mass (black arrow). Main stem of the facial nerve (yellow arrow) was involved.

Microscopically, the tumor was fairly well circumscribed but not encapsulated perfectly. It consisted of hypocellular to moderately cellular myxoid or fibromyxoid areas. Curvilinear capillaries with perivascular cell condensation were found. Fusiform tumor cells vary from small and bland to enlarged, bizarre, pleomorphic and multinucleated. The cytoplasm of the cells was scant and slightly eosinophilic, and mitoses were infrequent (Figure 3).
Figure 3

Photomicrograph of the tumor (H&E; ×100). Myxoid areas in association with spindle cells showing a pleomorphic storiform pattern as seen.

Immunohistochemical studies showed that the tumor cells expressed strong immunoreactivity for vimentin (VIM) and alpha1-antichymotrypsin (α1-ACT). Labeling index of Ki-67 (the number of Ki67 positive tumor cells divided by the sum of Ki67 positive and negative tumor cells) was 35% (Figure 4). Desmin (DES), alpha-smooth muscle actin (α-SMA), beta2-microglobulin (β2-MG) and cluster of differentiation 34 (CD34) assays were negative (Figure 5).
Figure 4

Positive immunohistochemical findings (immunoperoxidase technique; ×200). The tumor cells are positive for ACT (a) and VIM (b). Labeling index of Ki-67 (c) is 35%.

Figure 5

Negative immunohistochemical findings (immunoperoxidase technique; ×200). The tumor cells are negative for CD34 (a), DES (b), MG (c) and SMA (d).

Pathology revealed a T3N0M0 (AJCC 2002) parotid myxofibrosarcoma of low histological grade.

The patient's post-operative clinical course was uneventful. She was discharged on the six post-operative days. The right parotid received the full dose of radiation (68.4 Gy). The patient was free of disease 8 months after surgery.

Conclusions

Myxofibrosarcoma (MFS), one of soft tissue sarcomas with complex genomic profiles, shows gains and losses of numerous chromosomes or chromosome regions [2]. MFS was described firstly by Angervall as a group of fibroblastic lesions which has cellular distribution, pleomorphism of the nucleus, and mitotic activity that varies from a less cellular lesion with minimal cytologic atypia to a more cellular lesion [3]. As the commonest sarcoma affecting limbs of older patients [1, 35], high-grade (HG) lesions of MFS were considered to be a myxoid variant of malignant fibrous histiocytomas (MFH) by some investigators [6, 7], which was historically classified as a myxoid variant of MFH [8]. However, myxofibrosarcoma is now believed by many authors to be a clinically distinct entity [1, 8, 9]. They advocated naming it MFS instead of myxoid MFH. This is ascribed to the myxoid nodular appearance, characteristic curvilinear vasculatures, nuclear pleomorphism, histochemical staining, ultrastructural features and its clinicopathologic features [1, 4, 5, 10, 11].

According to the study of Antonescu CR and Baren A, basing on microscopic analysis, immunohistostaining by S100 and ultrastructural analysis will help us with the differential diagnosis between myxofibrosarcoma and fibromyxoid sarcoma [12]. Unfortunately, the latter two studies were not performed in this case. While microscopically, the spindled tumor cells, hyperchromatic and irregular nuclei, variable pleomorphism, scattered multinucleated or giant tumor cells and curvilinear-type vessels all verify the tumor is a myxofibrosarcoma instead of a fibromyxoid sarcoma.

Basing on the degree of cellularity, pleomorphism of the nucleus and mitotic activity, myxofibrosarcoma has been divided into three [1, 8] or four [1, 4, 8] grades. Low-grade myxofibrosarcoma has low malignancy with rare distant metastasis and high local recurrence rate (50-60%) [1, 4, 13], which is similar with that of the high-grade type. Sufficient surgical treatment is the most necessary to suppress local recurrence.

Myxofibrosarcoma is one of the commonest sarcomas of the elder's extremities. It often grows slowly and painlessly with almost equal incidence of men and women. In our case, the patient was just 37-year old, which makes it special. What's more, majority of the tumors are located in the subcutaneous tissue and form multiple gelatinous nodules, which tend to spread in a longitudinal manner. In the head and neck region, myxofibrosarcoma is uncommon. We found some case reports of myxofibrosarcoma in this region, such as in sphenoid sinus, maxillary sinus, hypopharynx, mandible and neck [1418]. There are also some reports of parotid sarcomas, such as sclerosing rhabdomyosarcoma, synovial sarcoma and interdigitating dendritic cell sarcoma (IDCS), but no myxofibrosarcoma [1921].

Parotid area swelling should always alert doctors. A unilateral swelling of the parotid implicates a possibility of a rare malignant myxofibrosarcoma. To our knowledge, this is the first case of parotid myxofibrosarcoma. It should be added to the differential diagnosis of diseases of the parotid. We have to recognize this disease and seek adequate treatment for it.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Declarations

Acknowledgements

We thank Hao Lou, Department of Otolaryngology-Head and Neck Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China for helping in the nursing processes of the patient.

Authors’ Affiliations

(1)
Department of Otolaryngology-Head and Neck Surgery, Xijing Hospital, Fourth Military Medical University
(2)
Department of Pathology, Xijing Hospital, Fourth Military Medical University

References

  1. Mentzel T, Calonje E, Wadden C, Camplejohn RS, Beham A, Smith MA, Fletcher CD: Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant. Am J Surg Pathol. 1996, 20: 391-405. 10.1097/00000478-199604000-00001.View ArticlePubMedGoogle Scholar
  2. Guillou L, Aurias A: Soft tissue sarcomas with complex genomic profiles. Virchows Arch. 2010, 456: 201-217. 10.1007/s00428-009-0853-4.View ArticlePubMedGoogle Scholar
  3. Angervall L, Kindblom LG, Merck C: Myxofibrosarcoma. Astudy of 30 cases. Acta Pathol Microbiol Scand A. 1977, 85A: 127-140.PubMedGoogle Scholar
  4. Hashimoto H, Enjoji M: Recurrent malignant fibroushistiocytoma. A histologic analysis of 50 cases. Am J SurgPathol. 1981, 5: 753-760.View ArticleGoogle Scholar
  5. Merck C, Angervall L, Kindblom LG, Odén A: Myxofibrosarcoma. A malignant soft tissue tumor of fibroblastic-histiocytic origin. A clinicopathologic and prognostic study of 110 cases using multivariate analysis. Acta Pathol Microbiol Immunol Scand Suppl. 1983, 282: 1-40.PubMedGoogle Scholar
  6. Oda Y, Tamiya S, Oshiro Y, Hachitanda Y, Kinukawa N, Iwamoto Y, Tsuneyoshi M: Reassessment and clinicopathological prognostic factors of malignant fibrous histiocytoma of soft parts. Pathol Int. 2002, 52: 595-606. 10.1046/j.1440-1827.2002.01399.x.View ArticlePubMedGoogle Scholar
  7. Weiss SW, Enzinger FM: Myxoid variant of malignant fibroushistiocytoma. Cancer. 1977, 39: 1672-1685. 10.1002/1097-0142(197704)39:4<1672::AID-CNCR2820390442>3.0.CO;2-C.View ArticlePubMedGoogle Scholar
  8. Huang HY, Lal P, Qin J, Brennan MF, Antonescu CR: Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems. Hum Pathol. 2004, 35: 612-621. 10.1016/j.humpath.2004.01.016.View ArticlePubMedGoogle Scholar
  9. Sington JD, Freeman A, Morris LS, Vowler SL, Arch BN, Fisher C, Coleman N: Minichromosome maintenance protein in myxofibrosarcoma. Mod Pathol. 2004, 17: 235-240. 10.1038/modpathol.3800044.View ArticlePubMedGoogle Scholar
  10. Erlandson RA, Woodruff JM: Role of electron microscopy in the evaluation of soft tissue neoplasms, with emphasis on spindle cell and pleomorphic tumors. Hum Pathol. 1998, 29: 1372-1381. 10.1016/S0046-8177(98)90005-3.View ArticlePubMedGoogle Scholar
  11. Kindblom LG, Merck C, Angervall L: The ultrastructure of myxofibrosarcoma. A study of 11 cases. Virchows Arch APathol Anat Histol. 1979, 381: 121-139. 10.1007/BF01257879.View ArticleGoogle Scholar
  12. Antonescu CR, Baren A: Spectrum of low-grade fibrosarcomas: a comparative ultrastructural analysis of low-grade myxofibrosarcoma and fibromyxoid sarcoma. Ultrastruct Pathol. 2004, 28: 321-332. 10.1080/019131290882259.View ArticlePubMedGoogle Scholar
  13. Merck C, Hagmar B: Myxofibrosarcoma: a correlative cytologic and histologic study of 13 cases examined by fine needle aspiration cytology. Acta Cytol. 1980, 24: 137-144.PubMedGoogle Scholar
  14. Lam PK, Trendell-Smith N, Li JH, Fan YW, Yuen AP: Myxofibrosarcoma of the sphenoid sinus. J Laryngol Otol. 2002, 116: 464-466.PubMedGoogle Scholar
  15. Pomerantz JM, Sanfacon DG, Dougherty TP, Hanson S: Myxofibrosarcoma of the maxillary sinus. Del Med J. 1982, 54: 147-152.PubMedGoogle Scholar
  16. Nishimura G, Sano D, Hanashi M, Yamanaka S, Tanigaki Y, Taguchi T, Horiuchi C, Matsuda H, Mikami Y, Tsukuda M: Myxofibrosarcoma of the hypopharynx. Auris Nasus Larynx. 2006, 33: 93-96. 10.1016/j.anl.2005.07.004.View ArticlePubMedGoogle Scholar
  17. Kummoona R: Central myxofibrosarcoma of the mandible treated by radical resection. Oral Surg Oral Med Oral Pathol. 1975, 39: 713-717. 10.1016/0030-4220(75)90031-6.View ArticlePubMedGoogle Scholar
  18. Udaka T, Yamamoto H, Shiomori T, Fujimura T, Suzuki H: Myxofibrosarcoma of the neck. J Laryngol Otol. 2006, 120: 872-874. 10.1017/S0022215106001113.View ArticlePubMedGoogle Scholar
  19. Lamovec J, Volavsek M: Sclerosing rhabdomyosarcoma of the parotid gland in an adult. Ann Diagn Pathol. 2009, 13: 334-338. 10.1016/j.anndiagpath.2009.02.002.View ArticlePubMedGoogle Scholar
  20. Kawata R, Terada T, Takenaka H, Kurisu Y, Tsuji M: Primary synovial sarcoma arising in the parotid region diagnosed by fluorescence in situ hybridization. Auris Nasus Larynx. 2008, 35: 583-586. 10.1016/j.anl.2007.12.003.View ArticlePubMedGoogle Scholar
  21. Efune G, Sumer BD, Sarode VR, Wang HY, Myers LL: Interdigitating dendritic cell sarcoma of the parotid gland: case report and literature review. Am J Otolaryngol. 2009, 30: 264-268. 10.1016/j.amjoto.2008.05.002.View ArticlePubMedGoogle Scholar
  22. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/246/prepub

Copyright

© Li et al; licensee BioMed Central Ltd. 2010

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement